At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 252 enrolled
Drug / intervention
Fluzoparib capsules +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With Fluzoparib Capsules Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
In Brief
A Phase 3 clinical trial evaluating Fluzoparib capsules and Placebo capsules for Ovarian Cancer. Completed, enrolled 252 participants across 1 site.
Detailed Summary
To evaluate the efficacy, safety tolerability of maintenance therapy with Fluzoparib(A PARP inhibitor) versus placebo in Chinese patients with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionJan 2022
Study CompletionJun 2025
TodayJul 2026
First PostedMar 5, 2019
Enrollment StartApr 30, 2019
Primary CompletionJan 10, 2022
Study CompletionJun 19, 2025
TodayJul 1, 2026
Enrollment to primary: 2.7 yearsPosted 7.3 years ago
Interventions
Fluzoparib capsulesdrug
Fluzoparib capsules
Placebo capsulesdrug
Placebo capsule